Alterations in lipid, amino acid, and energy metabolism distinguish Crohn’s disease from ulcerative colitis and control subjects by serum metabolomic profiling

Scoville, Elizabeth; Allaman, Margaret M.; Brown, Caroline T.; Motley, Amy K.; Horst, Sara; Williams, Christopher S.; Koyama, Tatsuki; Zhao, Zhiguo; Adams, Dawn W.; Beaulieu, Dawn B.; Schwartz, David A.; Wilson, Keith T.; Coburn, Lori A.

doi:10.1007/s11306-017-1311-y

Cited by 159 publications

(131 citation statements)

References 49 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Whereas, 286 serum metabolites were found to be significantly changed in CD patients compared with health subjects, only five metabolites were found to be decreased in patients with UC. Fatty acid, acylcarnitine metabolite, sphingolipid, and bile acid metabolism were significantly different in CD patients compared with UC patients and healthy controls (59). Serum metabolite profiles are also different in pediatric CD and UC patients (60).…”

Section: Metabolomicsmentioning

confidence: 94%

Serum Biomarkers for Inflammatory Bowel Disease

et al. 2020

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic, inflammatory disorder of the gastrointestinal tract. As the novel therapeutic goal and biologicals are widely recognized, accurate assessment of disease and prediction of therapeutic response have become a crucial challenge in clinical practice. Also, because of the continuously rising incidence, convenient and economical methods of diagnosis and clinical assessment are urgently needed. Recently, serum biomarkers have made a great progress and become a focus in IBD study because they are non-invasive, convenient, and relatively inexpensive than are markers in biopsy tissue, stool, breath, and other body fluids. Aims: To review the available data on serological biomarkers for IBD. Methods: We searched PubMed using predefined key words on relevant literatures of serum biomarkers regarding diagnosis, evaluation of therapeutic efficacy, surveillance of disease activity, and assessment of prognosis for IBD. Results: We reviewed serological biomarkers that are well-established and widely used (e.g., C-reactive protein), newly discovered biomarkers (e.g., cytokines, antibodies, and non-coding RNAs), and also recently advancements in serological biomarkers (e.g., metabolomics and proteomics) that are used in different aspects of IBD management. Conclusions: With such a wealth of researches, to date, there are still no ideal serum biomarkers for IBD. Serum profiling and non-coding RNAs are just starting to blossom but reveal great promise for future clinical practice. Combining different biomarkers can be valuable in improving performance of disease evaluation.

show abstract

Section: Metabolomicsmentioning

confidence: 94%

Serum Biomarkers for Inflammatory Bowel Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Recent analysis of the lipidome profiles of IBD patients also reflected the role of several pathways that are crucial for epithelial homeostasis, including barrier function and innate immune response [150]. Moreover, Scoville et al showed that the serum metabolomic profile in IBD patients reflected differences in a number of lipid, amino acid, and tricarboxylic acid cycle related metabolites when compared to the healthy controls [151]. In a more recent study, Murgia et al showed that using metabolomics and lipidomics, they were able to differentiate between IBD patients and healthy controls, and more importantly between CD and UC patients [152].…”

Section: Other Omics: Lipidomics and Metabolomics In Ibd Pathogenesismentioning

confidence: 99%

Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine

2019

View full text Add to dashboard Cite

Background: Inflammatory Bowel Disease (IBD) is a multifactorial chronic disease. Understanding only one aspect of IBD pathogenesis does not reflect the complex nature of IBD nor will it improve its clinical management. Therefore, it is vital to dissect the interactions between the different players in IBD pathogenesis in order to understand the biology of the disease and enhance its clinical outcomes. Aims:To provide an overview of the available omics data used to assess the potential mechanisms through which various players are contributing to IBD pathogenesis and propose a precision medicine model to fill the current knowledge gap in IBD.Results: Several studies have reported microbial dysbiosis, immune and metabolic dysregulation in IBD patients, however, this data is not sufficient to create signatures that can differentiate between the disease subtypes or between disease relapse and remission. Conclusions:We summarized the current knowledge in the application of omics in IBD patients, and we showed that the current knowledge gap in IBD hinders the improvements of clinical decision for treatment as well as the prediction of disease relapse. We propose one way to fill this gap by implementing integrative analysis of various omics datasets generated from one patient at a single time point.

show abstract

“…Carnitine also has an antioxidant and anti-inflammatory capacity [48,50]. Some studies have reported that acetyl-carnitine and carnitine are associated with liver function, liver diseases, neurologic disorders, and IBD [22,[51][52][53][54]. Therefore, liver damage due to intestinal inflammation occurs as a result of changes in the concentrations of acetyl-carnitine and carnitine.…”

Section: Discussionmentioning

confidence: 99%

Metabolomic Analysis of the Liver of a Dextran Sodium Sulfate-Induced Acute Colitis Mouse Model: Implications of the Gut–Liver Connection

Kim

Lee

Kwon

et al. 2020

Cells

View full text Add to dashboard Cite

The incidence of ulcerative colitis (UC) is increasing worldwide, and it has become a growing problem in Asia. Previous research on UC has focused on serum, plasma, urine, gut tissues, and fecal metabolic profiling, but a comprehensive investigation into the correlation between the severity of colitis and changes in liver metabolism is still lacking. Since the liver and gut exchange nutrients and metabolites through a complex network, intestinal diseases can affect both the liver and other organs. In the present study, concentration-dependent dextran sodium sulfate (DSS)-induced ulcerative colitis was employed to examine changes in liver metabolism using a proton nuclear magnetic resonance spectroscopy (1H-NMR)-and ultra-performance liquid chromatography time of flight mass spectroscopy (UPLC-TOF MS)-based metabolomics study. Using the multivariate statistical analysis method orthogonal projections to latent structures discriminant analysis (OPLS-DA), changes in metabolites depending on the DSS dose could be clearly distinguished. Specifically, hepatic metabolites involved in one-carbon metabolism, carnitine-related metabolism, and nucleotide synthesis were found to be affected by intestinal inflammation, implying the existence of a metabolic connection between the gut and liver. We are currently investigating the significance of this metabolic condition in UC.

show abstract

Alterations in lipid, amino acid, and energy metabolism distinguish Crohn’s disease from ulcerative colitis and control subjects by serum metabolomic profiling

Cited by 159 publications

References 49 publications

Serum Biomarkers for Inflammatory Bowel Disease

Serum Biomarkers for Inflammatory Bowel Disease

Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine

Metabolomic Analysis of the Liver of a Dextran Sodium Sulfate-Induced Acute Colitis Mouse Model: Implications of the Gut–Liver Connection

Contact Info

Product

Resources

About